Aromatherapy Inhaler Use for HSCT Distress

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Official Title

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Autologous and Allogeneic patients admitted to E1 for planned HSCT - Patients with hematologic malignancies requiring HSCT - No allergies to lavender or peppermint essential oils - Must have received chemotherapy during preparative regimen (single or multi-agent regimen) - Adult patient over 18 years of age - Able to speak, read, and comprehend English - Willing and capable of providing informed consent
Exclusion Criteria:
  1. - Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion - Patients receiving a transplant for a germ cell tumor diagnosis - Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration) - Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4 - History of scleroderma - History of atrial fibrillation - Known history of G6PD deficiency - Allergic to lavender or peppermint essential oils - Pediatric patient 18 years of age or less - Unable to speak, read, and comprehend English - Unwilling or incapable of providing informed consent


Aubrey L. Florom-Smith, PhD, RN, AFAsMA
Andrew Rezvani, M.D.
Andrew Rezvani, M.D.
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Medical oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)